Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

This phase II trial tests how well venetoclax with cladribine and cytarabine alternating with azacitidine and venetoclax works in treating patients with newly diagnosed monocytic acute myeloid leukemia (AML) and active signaling mutated AML. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as cladribine, cytarabine and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them

Trial Details

NCT ID
NCT06504459
Phase
PHASE2
Sponsor
OHSU Knight Cancer Institute
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Azacitidine
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Cladribine
  • Cytarabine
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366
  • Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

  • Ability to comprehend the investigational nature of the study and provide informed consent (i.e., participant or legally authorized representative …
  • Sign informed consent for the #4422 Biorepository prior to any study-specific procedures of interventions
  • Eligible AML patients of all races and ethnic groups will be considered for participation, irrespective of gender identity
  • Newly diagnosed, histologically confirmed monocytic AML, as defined by World Health Organization (WHO), or active signaling mutated AML defined as …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →